MDSAP: CURRENT STATUS AND FUTURE PLANS

Size: px
Start display at page:

Download "MDSAP: CURRENT STATUS AND FUTURE PLANS"

Transcription

1 MDSAP: CURRENT STATUS AND FUTURE PLANS Seminar hosted by DITTA in conjunction with IMDRF Monday, March Vancouver, BC, Canada

2 A few words about our friend Klaus Stitz:

3 MDSAP: CURRENT STATUS AND FUTURE PLANS OPENING REMARKS Patrick Hope Executive Director, MITA DITTA Chair Kimby Barton Interim Director of the Medical Devices Bureau, Health Canada

4 MDSAP: CURRENT STATUS AND FUTURE PLANS SESSION 1: REGULATOR PERSPECTIVES Marc-Henri Winter Staff Fellow, MDSAP - Center for Devices and Radiological Health U.S. Food and Drug Administration Fabio Quintino Pereira Manager - Office of GMP Inspection Brazilian Health Regulatory Agency - ANVISA

5 Medical Device Single Audit Program Overview of the Program and its Mechanics Marc-Henri Winter, Staff Fellow FDA

6 Participants and Observers Participants Therapeutics Goods Administration (TGA) Agência Nacional de Vigilância Sanitária (ANVISA) Health Canada Observers World Health Organization (WHO) European Union MHLW* and PMDA** Food and Drug Administration (FDA) * Ministry of Health, Labor and Welfare ** Pharmaceuticals and Medical Device Agency 6

7 Operational Organization Regulatory Authority Council (RAC) MDSAP governing body: two senior managers from each participating jurisdiction. representation from observing jurisdictions. Subject Matter Experts (SME) Permanent or ad-hoc working groups to: Develop policies and documents. Develop tools. Implement the program. 7

8 Concept RA Assess and recognize AO Share audit reports Audit and certify Make regulatory decisions Mfr RA: Regulatory Authority; AO: Auditing Organization; Mfr: Manufacturer 8

9 Audit Criteria ISO ( ) Regulatory requirements on Quality Systems Brazilian Good Manufacturing Practices (ANVISA RDC 16). Japanese requirements (MHLW MO 169). FDA s Quality System Regulation (21 CFR Part 820). Specific national requirements on: Registration of manufacturer sites. Licensing of medical device. Reporting adverse event and advisory notices. Device tracking. 9

10 Audit Method MDSAP Audit Model 10

11 Audit Method Recently updated to Align with ISO 13485:2016. Add clarifications on the audit of technical documentation. Add clarification on the audit of sterile products. Training modules: For auditors: Articulate-online (including quiz). For all: on the FDA CDRH Learn webpage. ( 11

12 Audit Nonconformity (NC) Grading GHTF/SG3/N19:2012 Quality management system Medical devices - Nonconformity Grading System for Regulatory Purposes and Information Exchange. QMS Impact Direct: 3 Indirect: 1 Repeat NC Yes: 1 No: 0 Lack of Document Yes: 1 No: 0 Released Device Yes: 1 No: 0 NC Grade = sum of 4 parameters, capped at 5 12

13 AO Journey To Recognition Assessment Activity Application reviewed favorably Status Application Received Stage 1 + Stage 2 (+ Critical Locations) + Response to any nonconformity deemed acceptable 3 Witnessed Audits + Response to any nonconformity deemed Recognition Decision acceptable Authorized to conduct MDSAP audits (the first 3 to be witnessed) Recognized 13

14 Auditing Organizations Application Received Authorized to Conduct MDSAP Audits Recognized 14

15 Manufacturer Participation Required to maintain Canadian Device Licences after Voluntary and encouraged to - Register devices in Australia especially combination products. Obtain ANVISA GMP certificate devices class III and IV. Substitute to PMDA audits. Substitute routine FDA inspections any devices. 15

16 International Value of MDSAP Europe will determine whether to become a participating member of the MDSAP coalition and if/ how they can use the outcomes of the program. WHO Prequalification of in vitro diagnostics use MDSAP audits to abbreviate or waive WHO inspections. Others advocacy towards the use of MDSAP certificates by non-participating Regulatory Authorities. 16

17

18 MDSAP consortium: Current status, Timelines and Plans Fábio P. Quintino MDSAP RAC Chair Office of GMP Inspection for Medical Devices, Sanitizers and Cosmetics ANVISA-Brazil

19 CONTENT HISTORY STATUS PERSPECTIVES

20 HISTORY From GHTF, IMDRF launched at planning meeting in Ottawa in October 2011 where ToR was drafted Singapore meeting (March 2012) marked official inauguration of IMDRF One of the 5 inaugural work items

21 IMDRF MDSAP WG PURPOSE Develop standard set of requirements for auditing organizations performing regulatory audits of medical device manufacturers quality management systems Represented a critical step in establishing any Medical Device Single Audit Project

22 IMDRF MDSAP WG OUTCOME Documents for the Regulatory Authority assessments of AOs are based on: IMDRF/MDSAP WG /N5 FINAL:2013 Regulatory Authority Assessment Method for the Recognition and Monitoring of Medical Device Auditing Organizations IMDRF/MDSAP WG /N6 FINAL:2013 Regulatory Authority Assessor Competence and Training Requirements IMDRF/MDSAP WG/N8 FINAL:2015 Regulatory Authority Assessment Method Guidance IMDRF/MDSAP WG/N11 FINAL:2014 MDSAP Assessment and Decision Process for the Recognition of an Auditing Organization

23 IMDRF MDSAP WG OUTCOME Recognition, monitoring and re-recognition of Auditing Organizations documents: IMDRF/MDSAP WG/N3FINAL:2013 Requirements for Medical Device Auditing Organizations for Regulatory Authority Recognition IMDRF/MDSAP WG/N4FINAL:2013 Competence and Training Requirements for Auditing Organizations IMDRF/MDSAP WG/N24 MDSAP Audit Report Guidance

24 Timeline SoC 11/2012: Signature of the Statement of Cooperation for the development of a single audit program (TGA; ANVISA; HC; US FDA) 03/2013: Accelerated plan to develop the basic structure for the 3 year pilot program starting on 01/01/ /2015: Japan (MHLW/PMDA) announces their participation in the pilot 12/2016: End of the pilot Transition to operational phase

25 CURRENT STATUS

26 MDSAP RECOGNIZED AOs BSI Group America Inc. Intertek Testing Services NA Inc. TŰV SŰD America Inc. 26

27 AOs AUTHORIZED TO PERFORM MDSAP AUDITS DEKRA Certification B.V. DQS Medzinprodukte GmBH LNE G-MED SAI Global Cert. Services PTY Ltd. SGS United Kingdom Ltd. TŰV Rheinland of North America Inc. TŰV USA Inc. UL Medical and Regulatory Services, UL LCC

28 AOs UNDER AUTHORIZATION PROCESS Lloid s Registry Quality Assurance Inc. - LRQA National Standards Authority of Ireland NSAI NSA Health Sciences Certification, LLC

29 As in march 9th

30 AUDIT NUMBERS 164 MDSAP Audits Reports to date 46 audits noted no nonconformities 118 audits had at least 1 nonconformity

31 Plans and Perspectives

32 Perspectives Pilot report to be issued An expected fast grow of the program in the transitional phase poses challenges Resource allocation MDSAP business model implementation Establishment of new RA

33 Regulatory Exchange Platform secure (REPs) IT solution to facilitate the exchange of confidential/non-public information (NPI), as well as the collaboration of regulators in a secure IT environment Starting with MDSAP module Partners: ANVISA Brazil, Health Canada, MHLW/PMDA Japan, TGA - Australia, US FDA and PAHO (Pan American Health Organization) Development phase started on March years are estimated for completion

34 Perspectives Increase of the use of program outcomes by each RA, maximizing value Learning curve, process improvements and program scale up may allow cost reduction

35 Perspectives Consolidation as a global, effective and resource wise tool for the regulatory oversight of Medical Device Manufacturer s QMS implementation.

36 Thanks for your Attention

37 MDSAP: CURRENT STATUS AND FUTURE PLANS SESSION 1: REGULATOR PERSPECTIVES Q&A

38 MDSAP: CURRENT STATUS AND FUTURE PLANS SESSION 2: ASSESSING ORGANIZATION (AO) PERSPECTIVES Gary Minks Vice President, Quality & Regulatory Affairs TÜV SÜD America Inc. Patricia Murphy Global Head, MDSAP Program BSI Healthcare

39 DITTA Seminar MDSAP; An Auditing Organization s Perspective Gary Minks TÜV SÜD America Inc Office: Mobile: gminks@tuvam.com TÜV SÜD 14/03/2017 Corporate Presentation Slide 39

40 Our heritage: 150 years of business success Establishment of a Mannheim-based steam boiler inspection association by 22 operators and owners of steam boilers, with the objective of protecting man, the environment and property against technology-related risks First vehicle periodic technical inspection (PTI) 1926 Introduction of the TÜV mark / stamp in Germany 1958 Development of a Bavaria-wide network of vehicle inspection centers in the late 1950s 1990s Conglomeration of TÜVs from the southern part of Germany to form TÜV SÜD and the expansion of business operations into Asia 2006 Expansion of services in ASEAN by acquiring Singapore-based PSB Group 2009 Launch of Turkey-wide vehicle inspection by TÜVTURK Today TÜV SÜD continues to pursue a strategy of internationalisation and growth TÜV SÜD TÜV SÜD Corporate presentation Slide 40

41 Achieve market success Manufacturing & industrial machinery Consumer products & retail Healthcare & medical devices Telecommunications & IT Services for components manufacturers, contractors, installation providers, equipment & material manufacturers and operators include: Component testing Periodic inspection of equipment Failure analysis System certification Training Services for manufacturers, retailers, buyers and suppliers of electrical & electronics, food, health & beauty, hardlines, softlines, toys & children s products: Testing Auditing Inspection Product certification Knowledge services System certification Training Services for medical device manufacturers and healthcare providers include: Clinical approvals Market approvals and certification Testing Evaluation System certification Training Services for equipment manufacturers and operators of infrastructure equipment and radio frequency wireless equipment include: Design reviews Testing Software escrow Product certification System certification Training TÜV SÜD TÜV SÜD Corporate presentation Slide 41

42 MDSAP - Successes Auditor on-line training for MDSAP program requirements. We are quickly ramping up our global MDSAP auditor capaciity. Collaboration between Regulators and Auditing Organizations during the pilot program Manufacturers have avoided US FDA and Australian TGA inspections. Manufacturers have used MDSAP audit reports to obtain ANVISA GMP certificates. TUV SUD is conducting combined MDSAP / European MDD audits. TÜV SÜD America Slide 42

43 MDSAP - Challenges Auditor Mentoring is a challenge in these early audits (i.e., pairing experienced auditors with first time auditors) Coverage of all 94 core tasks and regulatory authority specific tasks while conducting a Process Audit. The Audit Model works but it takes some experience. The auditors that have done several MDSAP audits report that they do get more comfortable over time. Realign task numbers to more logically align with sequence of audits TÜV SÜD America Slide 43

44 MDSAP - Challenges Combining MDSAP with European MDD (Medical Device Directive) audits. Adding MDD requirements into the Audit Model would help. Surveillance audit man-days for small organizations Manufacturer s concern with regulator information sharing Some customers change their attitude with MDSAP compared to previous audits. Scoping of multiple site audits (i.e., which sites to include) 15 day limit for manufacturers to respond to nonconformities Obtaining the correct DUNS numbers from manufacturers TÜV SÜD America Slide 44

45 DITTA MDSAP - Current Status and Future Plans Auditing Organization Perspective Successes & Challenges Copyright 2017 BSI. All rights reserved 45 14/03/2017

46 Program Distinctions Criteria ISO MDSAP Program Customer Manufacturer Regulator Output of success Auditing Organizations Qualification Certificate Competent Body Report & Certificate Regulators Audit Duration Employee count Fixed Timing Nonconformance grading Major/Minor 1, 2, 3, 4, 5

47 Pilot Phase 2014 thru 2016 Program Launches Copyright 2017 BSI. All rights reserved 47 14/03/2017

48 Program Launch Program Challenges 1. Jurisdictional requirements Interaction with ISO Complexity of differences Inclusion of CE 2. Locations How they interact Where they are located 3. Adoption by manufacturers 4. Length of audit Sufficient resources Organization of audit plan 5. Reporting Active voice All jurisdictions Specific timelines NCR grading Copyright 2017 BSI. All rights reserved 48 14/03/2017

49 Pilot Phase thru 2016 Audit Model Challenges Auditors Task-based Not ISO Plus Deep Dive into processes Regulatory Audit Risk key part of audit Manufacturers Confused by delivery Single audit Consistent flow Product - focused Risk focus support Copyright 2017 BSI. All rights reserved 49 14/03/2017

50 Pilot Program Successes 1. Auditing organizations jumped into the program and encouraged manufacturers to engage 2. Manufacturers recognized cost benefit 3. AO s embraced regulatory audit model 4. Five jurisdictions engaged 5. All stakeholders adapting to be successful Copyright 2017 BSI. All rights reserved 50 14/03/2017

51 Operational Phase 2017 Program Evolves Copyright 2017 BSI. All rights reserved 51 14/03/2017

52 Program settling in Changes evolved through the Pilot and into Operational Phase 1. Audit task timeline changes 2. Campus location defined 3. Additional auditing organizations progressing through qualifications 4. Manufacturers engagement growing dramatically in 2017, despite low numbers in Pilot phase Copyright 2017 BSI. All rights reserved 52 14/03/2017

53 Operational Phase beyond 2017 Copyright 2017 BSI. All rights reserved 53 14/03/2017

54 Program future outlook 1. New jurisdictions engage 2. Current jurisdictions expand use of MDSAP audit for other approvals Copyright 2017 BSI. All rights reserved 54 14/03/2017

55 MDSAP: CURRENT STATUS AND FUTURE PLANS SESSION 2: ASSESSING ORGANIZATION (AO) PERSPECTIVES Q&A

56 MDSAP: CURRENT STATUS AND FUTURE PLANS BREAK: 30 MINUTES Refreshments served in foyer

57 MDSAP: CURRENT STATUS AND FUTURE PLANS SESSION 3: REGULATED INDUSTRY PERSPECTIVES MDSAP Industry Participation Survey: Findings

58 MDSAP INDUSTRY PARTICIPATION SURVEY: FINDINGS Presented at MDSAP: Current Status and Future Plans Seminar hosted by DITTA in conjunction with IMDRF Monday, March Patrick Hope MITA Executive Director; DITTA Chair

59 MDSAP INDUSTRY PARTICIPATION SURVEY INTRODUCTION Objective: Improve industry participation in MDSAP Goal: Widespread adoption and use of MDSAP Survey methodology: Conducted online January 15-February participants

60 MDSAP INDUSTRY PARTICIPATION SURVEY MAJOR THEMES Most respondents did NOT participate in MDSAP pilot Those that DID participate found value in the program

61 Most participants only signed up 1 facility/manufacturing site MDSAP INDUSTRY PARTICIPATION SURVEY MAJOR THEMES

62 although they are planning to add more MDSAP INDUSTRY PARTICIPATION SURVEY MAJOR THEMES

63 Overall experience of participants: POSITIVE! MDSAP INDUSTRY PARTICIPATION SURVEY MAJOR THEMES

64 55% did not attempt, deterred by cost or lack of interest 10.5% attempted, but deterred by issues with cost or AO MDSAP INDUSTRY PARTICIPATION SURVEY NON-PARTICIPANTS, EXPLAINED

65 MDSAP INDUSTRY PARTICIPATION SURVEY NON-PARTICIPANTS, EXPLAINED 34% report their decision not to participate was based on other, often complex factors However: none so complex that they can t be fixed!

66 MDSAP INDUSTRY PARTICIPATION SURVEY GENERAL INFORMATION Most survey respondents sell into all MDSAP countries

67 MDSAP INDUSTRY PARTICIPATION SURVEY GENERAL INFORMATION More of respondents business is covered by MDSAP than is not

68 MDSAP INDUSTRY PARTICIPATION SURVEY GENERAL INFORMATION Most respondents used US FDA s online resources

69 MDSAP INDUSTRY PARTICIPATION SURVEY GENERAL INFORMATION Most respondents reported that the survey touched all aspects of concern with MDSAP

70 MDSAP INDUSTRY PARTICIPATION SURVEY TAKEAWAYS & NEXT STEPS Survey respondents that participated in MDSAP liked it Those that did not participate were open or planning to participate in MDSAP in the future

71 MDSAP INDUSTRY PARTICIPATION SURVEY TAKEAWAYS & NEXT STEPS MDSAP success depends on: Regulators wide use MDSAP as total replacement for current QMS audits Auditors have sufficient capacity to carry out all MDSAP audits by deadline Industry has sufficient time for all facilities to undergo MDSAP audit

72 THANK YOU!

73 MDSAP: CURRENT STATUS AND FUTURE PLANS SESSION 3: REGULATED INDUSTRY PERSPECTIVES Philip Steinborn Medtronic Emmett Deveraux Cook Medical Naoki Morooka Shimadzu Medical Systems Vijay Madikonda Johnson & Johnson Medical Devices

74 MEDTRONIC AND MDSAP Phil Steinborn VP, Quality/RA Americas

75 MDSAP IS HERE TO STAY MEDTRONIC IS COMMITTED TO PROGRAM 1. Achievements: Where are we with MDSAP? Challenges: What are the obstacles or risks as we see it? Suggestions: Our recommendations for industry and the program. 75

76 WHERE DO WE STAND WITH MDSAP? ACHIEVEMENTS 10+ FACILITIES ALREADY INSPECTED IN MDSAP PARTICIPATED IN PILOT PROGRAM NO OTHER INSPECTIONS AT MDSAP SITES TO DATE MDSAP CERTIFICATE ACCEPTED SEVERAL WITNESSED AUDITS. TO PERMIT AOs TO ATTAIN QUALIFICATION WORKING WITH MULTIPLE AOs SCHEDULING FOR OTHER FACILITIES PRIORITIZING CMDCAS SITES 76

77 WHAT ARE THE OBSTACLES OR RISKS? CHALLENGES CAPACITY OF PROGRAM CAN AOs MEET DEMAND? 4 AOs FULLY ACCREDITED 4 AOs IN WITNESSED AUDITS STAGE OF ACCREDITATION 5 AOs IN PRELIMINARY ASSESSMENT PROCESS DO AOs HAVE SUFFICIENT NUMBER OF MDSAP TRAINED AUDITORS? CAN WE GET TIMELY MDSAP AUDITS SCHEDULED? 77 COMPLEXITY OF AUDIT Significant preparation required. Audit to 5 different sets of regulations challenging. Annual inspection more frequent than usual for many of the participating regulators New process Experiencing some delays in getting audit reports can adversely impact registrations. Price tag for MDSAP audit significantly higher Are we saving with annual audits or does it balance out? RESPONSE FROM REGULATORS Regulators receiving annual MDSAP audit reports how will they react? FDA will treat Grade 4 and 5 findings as OAI (Official Action Indicated).. May result in Warning Letter. Regulators may send AOs back in to follow up on gaps in audit report (... or go themselves). Opportunity for regulators to uphold very particular requirements of their regulations.

78 OUR RECOMMENDATIONS FOR INDUSTRY AND PROGRAM SUGGESTIONS FOR INDUSTRY Prepare for the audits. Use the MDSAP Companion documents. Sticking points tend to be unique req ts of countries. Identify these! Engage AOs early. Get on their schedules and allow them to plan accordingly. Take AO findings seriously. Regulators are getting your reports. Don t forget about OEMs that are CMDCAS. They also need MDSAP. FOR PROGRAM Significant concerns about capacity. Availability of AOs and qualified auditors a real issue. Consider low risk manufacturers go to single surveillance over the 3 year cycle to help alleviate backlog. Current MDSAP model is not expandable. Audit is too complex with multiple sets of regulations. Need to align on a single audit standard (to meet local regulations) such as ISO 13485:

79 GOVERNMENT AFFAIRS Global Regulatory Developments An Industry Perspective on the Medical Device Single Audit Programme (MDSAP) COMPANY CONFIDENTIAL. DO NOT COPY. NOT FOR EXTERNAL DISTRIBUTION. GOVERNMENT AFFAIRS

80 COMPANY CONFIDENTIAL. DO NOT COPY. NOT FOR EXTERNAL DISTRIBUTION.

81 Cook Medical s history with MDSAP Volunteered for the program in December First Inspection was in April, 2015 (Witnessed AO Inspection) Second MDSAP Inspection February 2016 (Non Witnessed) We believe we were one of the first in Europe and the first Irish Site. Two manufacturing sites in Europe but Ireland was chosen as the test site. Great Team at the Cook Ireland site and the success is down to them. COMPANY CONFIDENTIAL. DO NOT COPY. NOT FOR EXTERNAL DISTRIBUTION. GOVERNMENT AFFAIRS

82 What this presentation is not going to be A detailed technical discussion on the Instead MDSAP it will be a very top level personal opinion of the MDSAP principle and achievements to-date COMPANY CONFIDENTIAL. DO NOT COPY. NOT FOR EXTERNAL DISTRIBUTION.

83 Overall comment Yes! Positive and to be welcomed COMPANY CONFIDENTIAL. DO NOT COPY. NOT FOR EXTERNAL DISTRIBUTION. GOVERNMENT AFFAIRS

84 Like anything new there are some concerns. Capacity concerns within the Auditing Organisations. The expansion of the MDSAP Programme Full benefits to Industry, incl. SMEs, yet to be realised Full EU Participation COMPANY CONFIDENTIAL. DO NOT COPY. NOT FOR EXTERNAL DISTRIBUTION. GOVERNMENT AFFAIRS

85 Capacity within the Auditing Organisations (AO) COMPANY CONFIDENTIAL. DO NOT COPY. NOT FOR EXTERNAL DISTRIBUTION. GOVERNMENT AFFAIRS

86 How many trained MDSAP Inspectors does each AO have? COMPANY CONFIDENTIAL. DO NOT COPY. NOT FOR EXTERNAL DISTRIBUTION. GOVERNMENT AFFAIRS

87 How many actual inspectors with the AOs with the MDSAP skill set? CLASS STERI CLINICAL MDD LOG ACTIVE COMPANY CONFIDENTIAL. DO NOT COPY. NOT FOR EXTERNAL DISTRIBUTION. GOVERNMENT AFFAIRS

88 The Global Expansion of the MDSAP Programme. COMPANY CONFIDENTIAL. DO NOT COPY. NOT FOR EXTERNAL DISTRIBUTION. GOVERNMENT AFFAIRS

89 Benefits for Industry yet to be fully realized It s a considerable expense so the benefits have to meet all expectations, incl SME s The principle is solid and its concept is one that industry and the patient will benefit from. The true benefit will come once the programme has developed and become truly global in nature. For now my advice is to stay involved but work with the Regulators to ensure that the benefits are realized for all stakeholders. COMPANY CONFIDENTIAL. DO NOT COPY. NOT FOR EXTERNAL DISTRIBUTION. GOVERNMENT AFFAIRS

90 Full EU Participation? EU have decided not to join the full programme. Resource Issues Industry would encourage that the EU come on board as a full member COMPANY CONFIDENTIAL. DO NOT COPY. NOT FOR EXTERNAL DISTRIBUTION. GOVERNMENT AFFAIRS

91 How did Industry respond to the MDSAP request for action? YOUR REGULATOR WANTS YOU! COMPANY CONFIDENTIAL. DO NOT COPY. NOT FOR EXTERNAL DISTRIBUTION. GOVERNMENT AFFAIRS

92 Participating manufacturers (June 2016) COMPANY CONFIDENTIAL. DO NOT COPY. NOT FOR EXTERNAL DISTRIBUTION. GOVERNMENT AFFAIRS

93 Overall score for Industry (My opinion) 5/10 We Passed but with much to do and to learn! COMPANY CONFIDENTIAL. DO NOT COPY. NOT FOR EXTERNAL DISTRIBUTION. GOVERNMENT AFFAIRS

94 Why do I say that? IMDRF as you know replaced the GHTF model 5 years ago Industry comments on IMDRF have been consistent We need to be at the table and be more than just observers. IMDRF gave us this opportunity for MDSAP but unfortunately we were slow in joining the pilot. Lets learn from this and move on together. COMPANY CONFIDENTIAL. DO NOT COPY. NOT FOR EXTERNAL DISTRIBUTION. GOVERNMENT AFFAIRS

95 Well done and please let it grow and expand and reach its full potential! COMPANY CONFIDENTIAL. DO NOT COPY. NOT FOR EXTERNAL DISTRIBUTION. CORP-D30444-EN GOVERNMENT AFFAIRS

96 Session 3 MDSAP Pilot Experience and Barriers to Participation in Japan Naoki Morooka Senior Manager, Quality Assurance Department Medical Systems Division, Shimadzu Corporation 13 March, 2017

97 Contents Introduction Consideration for implementation Steps for implementation Suggestion Additional Information of Speaker Naoki Morooka *SC member of DITTA *Chairman of QMS committee in JIRA. *Chairman of QMS committee in JFMDA. 97

98 Introduction - MDSAP Pilot in Japan Pilot stage in Japan 1 st Phase until 31 December nd Phase until 31 December 2018 For Approved Product Required documents by PMDA MDSAP report required for QMS inspection. Reduce the required documentation for Review by PMDA. For Certified Product Registered Certification Body also required to accept them. 98

99 Introduction -MDSAP Pilot in Japan Registered AOs Application Received Authorized to Conduct MDSAP Audits Recognition 13 organizations 11 organizations 3 organizations Almost AOs have local office in Japan. Ref.: List of AOs Implementation Japan into MDSAP pilot. Japanese QMS requirements were placed into Companion Document. And then, the auditors in AOs was trained according to Companion Document. PMDA received a few application for QMS inspection based on MDSAP report. Ref.: Companion Documents 99

100 Introduction -Company Profile and Certification Scope Company Profile Shimadzu Corporation Medical Systems Division Location: Kyoto, Japan Product/Certification Scope Diagnostic X-ray Devices Angiographic X-ray Diagnostic Systems Nuclear Medicine Diagnostic Systems Medical Image Managements Systems Near infrared fluorescence Imaging System(NIRS) Tumor-Tracking Systems for Radiotherapy Systems Certification/Auditing ISO13485:2003/ ISO9001 Angiography Systems Fluoroscopy Systems PET Scanner for Mammography Imaging CMDCAS, MDD Annex II, Japan-PMD Act MO169 All certifications were issued by same Certification Body. <Single Audit/ Multi-Certification/Report> US-FDA 21CFRpart 820, ANVISA, CFDA, etc. Audited by RA. General Radiography Systems Mobile X-ray Systems NIRS Systems Tumor-Tracking Systems for Radiotherapy Systems 100

101 Consideration Timing and Cycle for Certification Audit MDSAP Certification Audit For implementation of MDSAP, Certification Scope Extension was not considered in Audit Model. Full Audit required. Timing for Certification Audit Synchronize with existing Certification Cycles. in order to reduce the auditing cost. Transition period for Key Standards/Regulation MDSAP pilot 31 December ISO 9001: September CMDCAS 31 December ISO13485: February

102 Consideration Certification Cycles in our company Surveillance Audit Surveillance Audit Surveillance Audit Surveillance Audit Certification Audit Certification Audit Certification Audit Certification Audit Surveillance Audit Surveillance Audit Surveillance Audit Surveillance Audit Surveillance Audit Surveillance Audit Surveillance Audit Certification Audit Certification Audit Certification Audit Surveillance Audit Surveillance Audit Surveillance Audit Surveillance Audit Surveillance Audit Surveillance Audit Surveillance Audit Certification Audit ISO13485:2003 Cert. 3 years Cycle ISO13485:2016 Transition Period CMDCAS 3years Cycle MDSAP Transition Period ISO9001:2008 Cert. 3 years Cycle ISO9001:2015 Transition Period Surveilla Audit Our AO was not recognized yet Surveillance Audit Our Current Target Schedule Certification Audit Surveillance Audit Surveillance Audit MDSAP ISO13485:2016 ISO9001:2015 MDD or J-PMDAct 5years Cycle Surveillance Audit 102

103 Steps for implementation Steps Decision for schedule for Certification Audit as MDSAP Selection of AO Gap Analysis/Impact Assessments Modification/Adjustment for QMS Internal Audit Management Review Certification Audit by AO 103

104 Steps for implementation -Key elements Gap Analysis/Impact Assessments Details Audit Model MDSAP AU P Audit Model (PDF - 882KB) (ISO 13485:2003) MDSAP AU P Audit Model (PDF - 770KB) (ISO :2016) New Companion Document MDSAP AU G : Companion Document (PDF - 1.5MB) (ISO :2003) MDSAP AU G : Companion Document (PDF - 1.2MB) (ISO :2016) New Difference of Auditing Approach Top down approach Review for Subsystem (FDA-QSIT oriented) 104

105 Steps for implementation - key elements Sample description in Companion Document Chapter 1 - task 8. Verify that procedures have been defined, documented, and implemented for the control of documents and records of both internal and external origin required by the quality management system. Confirm the organization retains records and at least one obsolete copy of controlled documents for a period of time at least equivalent to the lifetime of the device, but not less than two years from the date of product release. Clause and Regulation: [ISO 13485:2016: 4.1.4, 4.2.1, 4.2.4, 4.2.5; TG(MD)R Sch3 P1 1.4(4); RDC ANVISA 16/2013: 3.1; MHLW MO169: 5, 6, 8, 9,; 21 CFR , ] Additional country-specific requirements: Australia (TGA): Confirm that Quality Management System documentation and records in relation to a device described in TG(MD)R Sch3 P1 1.9 are retained by the manufacturer for at least 5 years. Brazil (ANVISA): Verify that change records include a description of the change, identification of the affected documents, the signature of the approving individual(s), the approval date, and when the change becomes effective [RDC ANVISA 16/2013: 3.1.5]. Japan (MHLW) Confirm that Quality Management System documentation and records in relation to a device are retained for the following. 105

106 Steps for implementation -Key elements Consideration for Reporting For Deviation, Grading system was applied according to GHTF/SG3/N19:2012 Nonconformity Step 1 Grading Matrix Step 2 Escalation Rules Final Nonconformity Grade Grading Overview Grading Matrix Ref: 106

107 Suggestion For Regulators Scope Extension Audit Scope Extension Audit for ISO13485 Certification was not considered in Audit Model. Implementation Guide for Manufacturer. Manufacturer might need Implementation Guide for Manufacturer for better understanding for MDSAP. For Regulators and AOs Capacity of AOs in 2018/2019? So many company will request certification audit in 2018 or Do AOs have capability for them? For Industry Benefit We are considering to reduce auditing by US-FDA and ANVISA. 107

108 Medical Device Single Audit Program (MDSAP) Ethicon Experience Vijay Kumar Madikonda Ethicon Compliance March 13, 2017

109 Agenda Ethicon Inc. Achievements Audit Experience & Challenges Suggestions/Feedback on the MDSAP Program Confidential For J&J Use Only 10 9

110 Achievements: MDSAP Pilot Update Ethicon and Mentor Business units of J&J participated in the MDSAP Pilot Program. Details of the sites piloted for the MDSAP are as follows: SITE Ethicon LLC, San Lorenzo Most recent MDSAP audit dates May 19-22, 2015 & Mar 15-18, 2016 Type of Audit Site Activities Product supply MDSAP Surveillance MDSAP Surveillance Manufacturer WW supply including US, Canada, Australia, Brazil & Japan Ethicon SARL, Neuchatel Aug 25-27, 2015 & June 28-July 1, 2016 Ethicon Inc., Somerville Dec 1-2, 2015 Jun 1-3, 2016 MDSAP Certification MDSAP Surveillance MDSAP Surveillance MDSAP Surveillance Manufacturer Design, Regulatory, PMS, Complaint handling WW supply including US, Canada, Australia, Brazil & Japan WW supply including US, Canada, Australia, Brazil & Japan Ethicon Inc., Durango, Juarez Jun 7-8, 2016 MDSAP Surveillance Manufacturer WW supply including US, Canada, Australia, Brazil & Japan Mentor Irving July 14-18, 2015 June 21-24, 2016 MDSAP Certification MDSAP Surveillance Design, RA, PMS, CQ, Mfg. WW supply including US, Canada, Australia, Brazil & Japan MDSAP Plans for 2017: Added 6 more Ethicon sites to the MDSAP program and inspections scheduled in Multiple J&J Medical device sites are moving into MDSAP program. Confidential For J&J Use Only 11 0

111 Audit Experience & Challenges Audit Process: Transparent and Task-based Audit Model follows Companion Document Very thorough audits and evaluated compliance to all regulations Audit Duration: Longer audit times No significant difference between Recertification and Surveillance audit time. Challenges: Challenges in scheduling of the Audits due to limited trained auditors. Review of some information not related to the site scope (design, complaint handling, Regulatory, Quality systems) required Franchise participation in each site audits. Confidential For J&J Use Only 11 1

112 Feedback on the MDSAP Program: Positive: Well trained auditing organizations conducting audits in a consistent way. Suggestions/Opportunities: Train more auditors to support full MDSAP implementation. Training materials and Guidance available of MDSAP website. Timely issuance of audit reports and MDSAP certificates. Reduction in the number of Audits & Less business disruption. Harmonization of requirements. Expand the scope of MDSAP acceptability to include For cause inspections as AO s can conduct Special audits to follow-up on Post market issues, significant findings from previous audits and based on request from participating regulatory authorities. Post audit timeline of D for providing evidence of implementation of remediation actions addressing Grade 4 or 5 observations is too short if robust actions are to be implemented. Confidential For J&J Use Only 11 2

113 Thank you Confidential For J&J Use Only 11 3

114 MDSAP: CURRENT STATUS AND FUTURE PLANS SESSION 3: REGULATED INDUSTRY PERSPECTIVES Q&A

115 MDSAP: CURRENT STATUS AND FUTURE PLANS CLOSING SESSION: PANEL DISCUSSION Moderator: Brian Lewis, MEDEC Marc-Henri Winter - USFDA Jun Kitahara PMDA Japan Nancy Shadeed Health Canada Cheryl McCrae TGA Australia Fabio Quintino Pereira ANVISA Brazil Gary Minks TÜV SÜD America Inc. Patricia Murphy BSI Healthcare

116 MDSAP: CURRENT STATUS AND FUTURE PLANS CLOSING SESSION: PANEL DISCUSSION Q&A

117 MDSAP: CURRENT STATUS AND FUTURE PLANS Thank you!

Medical Device Single Audit Program (MDSAP)

Medical Device Single Audit Program (MDSAP) Medical Device Single Audit Program (MDSAP) Kimberly A. Trautman Executive Vice President, Medical Device International Services Health Sciences Medical Devices NSF International This document is intended

More information

Medical Device Single Audit Program (MDSAP) An Overview Canadian Experience

Medical Device Single Audit Program (MDSAP) An Overview Canadian Experience Medical Device Single Audit Program (MDSAP) An Overview Canadian Experience Linda Chatwin Sr. Customer Solutions Consultant : 360-817-5556 : linda.chatwin@ul.com LINDA M CHATWIN, Esq, RAC Biography Ms.

More information

Medical Device Single Audit Program (MDSAP) Key Points

Medical Device Single Audit Program (MDSAP) Key Points Medical Device Single Audit Program (MDSAP) Key Points March 2017 Copyright 2016 BSI. All rights reserved. Copyright 2012 BSI. All rights reserved. 1 What is MDSAP? How does MDSAP work? How does MDSAP

More information

Medical Device Single Audit Program (MDSAP)

Medical Device Single Audit Program (MDSAP) Medical Device Single Audit Program (MDSAP) October 2017 Roadshow Copyright 2016 BSI. All rights reserved. Copyright 2012 BSI. All rights reserved. 1 How MDSAP works Timelines and Status Auditing Organization

More information

MDSAP Me M dical D e D vice S i S ngle Audit Program

MDSAP Me M dical D e D vice S i S ngle Audit Program MDSAP Medical Device Single Audit Program Gary Minks VP, Quality & Regulatory Affairs TÜV SÜD America Inc. gminks@tuvam.com Revision: 2013(09(29 TÜV SÜD America 13(04(29 Slide 1 IMDRF International Medical

More information

5 Countries. 1 Unified Audit.

5 Countries. 1 Unified Audit. 5 Countries. 1 Unified Audit. UNDERSTANDING THE MEDICAL DEVICE SINGLE AUDIT PROGRAM (MDSAP) Melodie Kahl, Mike Wolf, and Scott Edwards July 2017 For more information, please contact: USA Office: + 1 877

More information

MDSAP Overview Marseille,

MDSAP Overview Marseille, MDSAP Overview Marseille, 20.10.2017 Sigrid Krimmer-Quendler PhD, MSc EMEA Client Manager MDSAP Support Specialist Copyright 2016 BSI. All rights reserved. 1 Who is this woman?!? Sigrid Krimmer-Quendler

More information

Medical Device Single Audit Program (MDSAP)

Medical Device Single Audit Program (MDSAP) Medical Device Single Audit Program (MDSAP) Paul Brooks Senior Vice President BSI Healthcare Solutions Copyright 2015 BSI. All rights reserved. 1 Agenda What is MDSAP? How does MDSAP work? I already have

More information

MDSAP AUDIT PROCESS. A Manufacturer s Perspective. Connie Hoy EVP Regulatory Affairs Cynosure, Inc.

MDSAP AUDIT PROCESS. A Manufacturer s Perspective. Connie Hoy EVP Regulatory Affairs Cynosure, Inc. MDSAP AUDIT PROCESS A Manufacturer s Perspective Connie Hoy EVP Regulatory Affairs Cynosure, Inc. Cynosure Located in Westford, MA Largest manufacturer of Medical Lasers Second location in Hicksville,

More information

Medical Device Single Audit Program (MDSAP) Copyright 2014 BSI. All rights reserved.

Medical Device Single Audit Program (MDSAP) Copyright 2014 BSI. All rights reserved. Medical Device Single Audit Program (MDSAP) International Medical Device Regulatory Forum (IMDRF) IMDRF Management Committee (MC) regulators: Australia, Brazil, Canada, China, the European Union, Japan

More information

EU Unannounced Audits (UAV) Experience To Date Medical Device Single Audit Program (MDSAP) Copyright 2015 BSI. All rights reserved.

EU Unannounced Audits (UAV) Experience To Date Medical Device Single Audit Program (MDSAP) Copyright 2015 BSI. All rights reserved. EU Unannounced Audits (UAV) Experience To Date Medical Device Single Audit Program (MDSAP) Copyright 2015 BSI. All rights reserved. Background & Requirements - See Webinars BSI Website Copyright 2015 BSI.

More information

Trial acceptance of MDSAP audit reports in Japan

Trial acceptance of MDSAP audit reports in Japan Trial acceptance of MDSAP audit reports in Japan Pharmaceuticals and Medical Devices Agency (PMDA), Office of Manufacturing / Quality and Compliance March 2018 1 Japan s participation to MDSAP International

More information

FINAL DOCUMENT. International Medical Device Regulators Forum. Medical Device Regulatory Audit Reports

FINAL DOCUMENT. International Medical Device Regulators Forum. Medical Device Regulatory Audit Reports FINAL DOCUMENT International Medical Device Regulators Forum Title: Authoring Group: Medical Device Regulatory Audit Reports IMDRF MDSAP Working Group Date: 2 October 2015 Toshiyoshi Tominaga, IMDRF Chair

More information

IVD Inspections Technical Update Dr Dragana Milic Medical devices inspections

IVD Inspections Technical Update Dr Dragana Milic Medical devices inspections IVD Inspections Technical Update 2018 Dr Dragana Milic Medical devices inspections 1 Objectives Harmonisation - internal and external (PQ Medicines/Vaccines/Vector Control and MDSAP) Transparency (clarify

More information

ISO 13485:2016 Medical Devices-Quality Management Systems- Requirements for Regulatory Purposes. Theresa McCarthy

ISO 13485:2016 Medical Devices-Quality Management Systems- Requirements for Regulatory Purposes. Theresa McCarthy ISO 13485:2016 Medical Devices-Quality Management Systems- Requirements for Regulatory Purposes Theresa McCarthy Welcome and Introductions Please interview and collect: Name Primary Quality Management

More information

Contents. Regulatory Bodies... 13

Contents. Regulatory Bodies... 13 Contents UNITED STATES... 3 Regulatory Bodies... 3 Product Classification and Regulatory Control... 3 Application Documents... 3 Quality System Requirements... 4 Product and Manufacturer s License... 4

More information

CANADA (HEALTH CANADA)

CANADA (HEALTH CANADA) 1 GMP GAZETTE TM January 2016 HPFBI CANADA (HEALTH CANADA) NNHPD NHPs Notice to Stakeholders Regarding Site Licensing Update Who s affected? Manufacturers, packagers, labellers, importers, and distributors

More information

Auditing Within the Culture of the Medical Device Industry & ISO 13485:2016 Overview. ASQ Quality Conference 2017 for Region 5 October 25, 2017

Auditing Within the Culture of the Medical Device Industry & ISO 13485:2016 Overview. ASQ Quality Conference 2017 for Region 5 October 25, 2017 Auditing Within the Culture of the Medical Device Industry & ISO 13485:2016 Overview ASQ Quality Conference 2017 for Region 5 October 25, 2017 Introduction / Purpose Discuss the influences of regulatory

More information

Hosting Inspections from foreign countries: PMDA (Japan) ANVISA (Brazil)

Hosting Inspections from foreign countries: PMDA (Japan) ANVISA (Brazil) Hosting Inspections from foreign countries: PMDA (Japan) ANVISA (Brazil) Kathrin Abelein Vice President Quality, R-Pharm, JSC First Russian GMP Conference 20. 22. September 2016 Agenda General information

More information

Medical Device Single Audit Program (MDSAP)

Medical Device Single Audit Program (MDSAP) Medical Device Single Audit Program (MDSAP) IMDRF MDSAP International Medical Device Regulators Forum Medical Device Single Audit Program IMDRF recognises that a global approach to auditing and monitoring

More information

Editor : Francoise SCHLEMMER Date : 09/03/2015 IMDRF, March 9 th 2015 REPORT Present : Hans-Heiner Junker Francoise SCHLEMMER

Editor : Francoise SCHLEMMER Date : 09/03/2015 IMDRF, March 9 th 2015 REPORT Present : Hans-Heiner Junker Francoise SCHLEMMER The European Association Medical Devices - Notified Bodies TEAM-NB A.I.S.B.L. Boulevard Frère Orban 35A B 4000 Liège BELGIQUE Tél.: + 32 (0)4 254 55 88 Fax: + 32 (0)4 254 55 89 E-mail: secretary@team-nb.org

More information

MEDICAL DEVICE CLINICAL INVESTIGATIONS AND ISO 14155

MEDICAL DEVICE CLINICAL INVESTIGATIONS AND ISO 14155 MEDICAL DEVICE CLINICAL INVESTIGATIONS AND ISO 14155 EXECUTIVE SUMMARY Medical device regulations around the world generally require manufacturers of most types of medical devices to supply data as part

More information

Course Title ID Duration Basic Premium. Biological Evaluation of Medical Devices: A Risk-Based Approach N mins

Course Title ID Duration Basic Premium. Biological Evaluation of Medical Devices: A Risk-Based Approach N mins Pre-Clinical Basic Level : CMDA Certified Medical Device Associate Biological Evaluation of Medical Devices: A Risk-Based Approach N134 63 mins 186.00 144.00 Introduction to Process Validation N135 75

More information

ABRIDGED PREQUALIFICATION ASSESSMENT. Prequalification of In Vitro Diagnostics

ABRIDGED PREQUALIFICATION ASSESSMENT. Prequalification of In Vitro Diagnostics P r e q u a l i f i c a t i o n T e a m - D i a g n o s t i c s ABRIDGED PREQUALIFICATION ASSESSMENT Prequalification of In Vitro Diagnostics PQDx_173 v3 12 September 2017 (This document version supersedes

More information

AAMI Quality Systems White Paper

AAMI Quality Systems White Paper AAMI s White Paper Comparison of 21 CFR Part 820 to ISO 13485:2016 February 2017, Updated February 2018 AUTHORS Seb Clerkin, GMP Advisory Services Nicola Martin, Owner, Nicola Martin Consulting Jack Ward,

More information

Document issued on: March 19, The draft of this document was issued on May 20, 2010.

Document issued on: March 19, The draft of this document was issued on May 20, 2010. Reprinted from FDA s website by Guidance for Industry, Third Parties and Food and Drug Administration Staff Medical Device ISO 13485:2003 Voluntary Audit Report Submission Pilot Program Document issued

More information

Expert Commentary on BS EN ISO 13485:2016, Medical devices Quality management systems Requirements for regulatory purposes

Expert Commentary on BS EN ISO 13485:2016, Medical devices Quality management systems Requirements for regulatory purposes Expert Commentary on BS EN ISO 13485:2016, Medical devices Quality management systems Requirements for regulatory purposes Author: Eamonn Hoxey, PhD, F.R.Pharm.S., Vice President, Medical Devices Quality

More information

ISO Introduction and Background

ISO Introduction and Background ISO 13485 Introduction and Background After more than 10 years, the updated Quality Management standard with the revision of ISO 13485 for the medical device industry is here. The origins of ISO 13485

More information

Panel Discussion: European Medical Device Regulations Preparing for the Storm Moderator: Lenita Y. Sims Spears, Senior Quality Consultant/Senior

Panel Discussion: European Medical Device Regulations Preparing for the Storm Moderator: Lenita Y. Sims Spears, Senior Quality Consultant/Senior Panel Discussion: European Medical Device Regulations Preparing for the Storm Moderator: Lenita Y. Sims Spears, Senior Quality Consultant/Senior Regulatory and Compliance Counsel, BioTeknica Panelists:

More information

Medical Device Product Innovation

Medical Device Product Innovation Medical Device Product Innovation Madoka Murakami PMDA, Japan AMDC Industry Training, 3-5 Oct 2017, Surabaya Agenda Introduction of PMDA Medical Device TPLC and Quality Management Typical Nonconformities

More information

Final Document. 18 September 2014

Final Document. 18 September 2014 IMDRFIMDSAP WG/N11FINAL:2014 International Medical Device Regulators Forum Final Document Title: MD SAP Assessment and Decision Process for the Recognition of an Auditing Organization Authoring Group:

More information

UNICEF TECHNICAL REQUIREMENTS FOR MEDICAL DEVICES (MD)

UNICEF TECHNICAL REQUIREMENTS FOR MEDICAL DEVICES (MD) UNICEF TECHNICAL REQUIREMENTS FOR MEDICAL DEVICES (MD) A. Background January 2019 UNICEF Technical requirements for Medical Devices are the requirements that suppliers need to comply with, and that products

More information

NOTICE. Re: Guidance Document GD211: Guidance on the Content of Quality Management System audit reports

NOTICE. Re: Guidance Document GD211: Guidance on the Content of Quality Management System audit reports June 8, 2011 NOTICE Our file number: 11-110913-528 Re: Quality Management System audit reports is pleased to announce the release of the guidance document GD211: Guidance on the Content of. A draft version

More information

DITTA CONTRIBUTION TO IMDRF STAKEHOLDER FORUM

DITTA CONTRIBUTION TO IMDRF STAKEHOLDER FORUM DITTA CONTRIBUTION TO IMDRF STAKEHOLDER FORUM Satoshi Kimura DITTA Chair JIRA Executive Director IMDRF Stakeholder Forum Tokyo, 25 Mar. 2015 Key Topics Updates about DITTA DITTA views on current work items

More information

Progress of QMS/QSD WG

Progress of QMS/QSD WG 4th Joint Conference of Japan and Taiwan Progress of QMS/QSD WG Katsuya SAWADAISHI Office of Manufacturing/Quality and Compliance Division of Medical Devices December 7th, 2016 Main Topics 1. QSD/QMS WG

More information

WHO Prequalification of In Vitro Diagnostics Programme

WHO Prequalification of In Vitro Diagnostics Programme P r e q u a l i f i c a t i o n T e a m - D i a g n o s t i c s Information for Manufacturers on the Manufacturing Site(s) Inspection (Assessment of the Quality Management System) WHO Prequalification

More information

Japan Update - Implementation of PMD Act - March, 2015

Japan Update - Implementation of PMD Act - March, 2015 Japan Update - Implementation of PMD Act - March, 2015 Topics Implementation of PMD Act; Revision of Pharmaceutical Affairs Law (PAL) PMDA Medical Device Training Seminar 2 Implementation of PMD Act: The

More information

PROPOSED DOCUMENT. Global Harmonization Task Force

PROPOSED DOCUMENT. Global Harmonization Task Force PROPOSED DOCUMENT Global Harmonization Task Force Title: Quality management system Medical devices - Nonconformity Grading System for Regulatory Purposes and Information Exchange Authoring Group: Study

More information

COCIR/MITA Joint Contribution. EU and US call for input on regulatory issues for possible future trade agreement

COCIR/MITA Joint Contribution. EU and US call for input on regulatory issues for possible future trade agreement COCIR/MITA Joint Contribution EU and US call for input on regulatory issues for possible future trade agreement COCIR and MITA welcome the opportunity to share ideas with the United States government and

More information

IMDRF. Final Document. Regulatory Authority Assessor Competence and Training Requirements. IMDRF MDSAP Work Group

IMDRF. Final Document. Regulatory Authority Assessor Competence and Training Requirements. IMDRF MDSAP Work Group IMDRF/ WG /N6 FINAL:2013 IMDRF International Medical Device Regulators Forum Final Document Title: Authoring Group: Regulatory Authority Assessor Competence and Training Requirements IMDRF MDSAP Work Group

More information

Complete global Solutions

Complete global Solutions Complete global Solutions for ELECtro-Medical devices get your product to market faster we know the way 1 sgs medical network THE As a medical devices manufacturer your focus is to create products that

More information

2 DAY WORKSHOP on Preparing For The New EU Medical Device Regulations (MDR)

2 DAY WORKSHOP on Preparing For The New EU Medical Device Regulations (MDR) WORLD COMPLIANCE SEMINARS SPEAKER:- DAVID R DILLS Regulatory Affairs & Compliance Consultant 2 DAY WORKSHOP on Preparing For The New EU Medical Device Regulations (MDR) 21-22, FEB- 2018 Burlingame CA Course

More information

2 DAY WORKSHOP on Preparing For The New EU Medical Device Regulations (MDR)

2 DAY WORKSHOP on Preparing For The New EU Medical Device Regulations (MDR) WORLD COMPLIANCE SEMINARS SPEAKER:- DAVID R DILLS Regulatory Affairs & Compliance Consultant 2 DAY WORKSHOP on Preparing For The New EU Medical Device Regulations (MDR) 21-22, FEB- 2018 Burlingame CA Course

More information

Prequalification of in vitro diagnostics - Technical Update 24 November 2015

Prequalification of in vitro diagnostics - Technical Update 24 November 2015 Prequalification of in vitro diagnostics - Technical Update 24 November 2015 Copenhagen, Denmark 22-26 November 2015 1 Product Dossier Copenhagen, Denmark 22-26 November 2015 2 PQDx Data Quality Expectations

More information

ELECtro-Medical devices. in trusted hands. sgs is the world s leading

ELECtro-Medical devices. in trusted hands. sgs is the world s leading ELECTRICAL & ELECTRONICS electro MEDICAL DEVICES ELECtro-Medical devices in trusted hands sgs is the world s leading testing and certification company 1 sgs medical network: THE As a medical devices manufacturer

More information

ASQ Tappan Zee Section Medical Devices, New Regulations and Standards. 26 th September / V. Fischer / Rev. 01

ASQ Tappan Zee Section Medical Devices, New Regulations and Standards. 26 th September / V. Fischer / Rev. 01 ASQ Tappan Zee Section Medical Devices, New Regulations and Standards 26 th September / V. Fischer / Rev. 01 Agenda Medical Device, General Aspects Examples Quality System(s) New Regulations & Standards

More information

MEDICINES CONTROL COUNCIL

MEDICINES CONTROL COUNCIL MEDICINES CONTROL COUNCIL GUIDELINE FOR A LICENCE TO MANUFACTURE, IMPORT, EXPORT OR DISTRIBUTE MEDICAL DEVICES & IVDs This guideline is intended to provide recommendations to applicants wishing to submit

More information

Trinity College Dublin QP Forum 2017 Tuesday 25 th April

Trinity College Dublin QP Forum 2017 Tuesday 25 th April Trinity College Dublin QP Forum 2017 Tuesday 25 th April HPRA QUESTIONS & ANSWERS 1. What is the approach being taken for audit of contamination control strategies as per chapters 3 & 5? What is the current

More information

WHO Prequalification of In Vitro Diagnostics

WHO Prequalification of In Vitro Diagnostics WHO Prequalification of In Vitro Diagnostics 3 rd WHO Global Forum on Medical Devices Geneva, 10 May 2017 Helena Ardura & Deirdre Healy WHO PQ Team Diagnostics Assessment Essential Medicines and Health

More information

CBI s 15 th Annual Product Complaints Congress for Life Sciences

CBI s 15 th Annual Product Complaints Congress for Life Sciences CBI s 15 th Annual Product Complaints Congress for Life Sciences June 14, 2017 Steven Niedelman Lead Quality Systems & Compliance Consultant King & Spalding LLP 1700 Pennsylvania Ave., NW Washington, DC

More information

Update on Regulatory Environment- Europe Experience with 2007/47/EC M5 & Discussions on Possible Recast of EU Medical Device Regulations

Update on Regulatory Environment- Europe Experience with 2007/47/EC M5 & Discussions on Possible Recast of EU Medical Device Regulations Update on Regulatory Environment- Europe Experience with 2007/47/EC M5 & Discussions on Possible Recast of EU Medical Device Regulations Paul Brooks Vice President Healthcare, Americas Presentation to:

More information

Excipient Certification: Schemes and Auditable Standards - the role in Supplier Qualification

Excipient Certification: Schemes and Auditable Standards - the role in Supplier Qualification Excipient Certification: Schemes and Auditable Standards - the role in Supplier Qualification European Compliance Academy Vienna, 20 th & 21 st October 2009 Dr Iain Moore Chair Certification Committee

More information

SUMMARY REPORT OF THE SG1 MEETING HELD ON 18/19 th FEBRUARY 2004 IN CANBERRA

SUMMARY REPORT OF THE SG1 MEETING HELD ON 18/19 th FEBRUARY 2004 IN CANBERRA SUMMARY REPORT OF THE SG1 MEETING HELD ON 18/19 th FEBRUARY 2004 IN CANBERRA Attendees Europe Maurice Freeman - Chairman Alan Kent Secretary Elke Lehmann BfArM, Germany Benny Ons EDMA/EMIG Petra Kaars-Wiele

More information

The Third Annual BSI Medical Device Regulatory Road Shows

The Third Annual BSI Medical Device Regulatory Road Shows The Third Annual BSI Medical Device Regulatory Road Shows September 2014 Monday, September 8, 2014 Santa Clara Biltmore Friday, September 12, 2014 Boston Marriott Burlington Wednesday, September 10, 2014

More information

Quality and GMP Compliance for Virtual Companies (Pharmaceutical, Medical Device & Biologics Industries)

Quality and GMP Compliance for Virtual Companies (Pharmaceutical, Medical Device & Biologics Industries) Quality and GMP Compliance for Virtual Companies (Pharmaceutical, Medical Device & Biologics Industries) *** LIMITED TIME OFFER: FREE $100 AMAZON GIFT CARD! *** REGISTER TODAY! Today, many companies operate

More information

GxP Auditing, Remediation, and Staff Augmentation

GxP Auditing, Remediation, and Staff Augmentation GxP Auditing, Remediation, and Staff Augmentation TABLE OF CONTENTS 3 Introduction 4 GxP Auditing 4 GMP Auditing 5 GCP Auditing 5 GLP Auditing 6 Pharmacovigilance Auditing 6 Vendor/Supplier Auditing 7

More information

1. GMP/Quality issues Report back from the discussion in last year s symposium

1. GMP/Quality issues Report back from the discussion in last year s symposium 2 nd Japan - India Medical Products Regulation Symposium 1. GMP/Quality issues Report back from the discussion in last year s symposium Mr. Fumihito Takanashi, Office of International Regulatory Affairs

More information

Diagnostics new product development: overview, WHO s scientific and regulatory role, regulatory pathways and demand creation

Diagnostics new product development: overview, WHO s scientific and regulatory role, regulatory pathways and demand creation Diagnostics new product development: overview, WHO s scientific and regulatory role, regulatory pathways and demand creation Irena Prat Technical Officer, PQDx 1 Global Dx regulatory landscape Dx regulation

More information

AAMI Quality Systems White Paper: Comparison of 21 CFR Part 820 to ISO 13485:2016 1

AAMI Quality Systems White Paper: Comparison of 21 CFR Part 820 to ISO 13485:2016 1 AAMI s White Paper Comparison of 21 CFR Part 820 to ISO 13485:2016 February 2017 AUTHORS Seb Clerkin, GMP Advisory Services Nicola Martin, Owner, Nicola Martin Consulting Jack Ward, Owner, Ward Sciences

More information

DITTA STANDARDS. What makes a standards a great standard. Industry View. September 2017 Ottawa, Canada

DITTA STANDARDS. What makes a standards a great standard. Industry View. September 2017 Ottawa, Canada DITTA STANDARDS What makes a standards a great standard Industry View September 2017 Ottawa, Canada Elisabeth George Philips Head of Global Regulations & Standards MEDICAL DEVICE INDUSTRY PERSPECTIVE Introduction

More information

Drug Quality Assurance: Systems at ChemCon Author: Dr. Peter Gockel

Drug Quality Assurance: Systems at ChemCon Author: Dr. Peter Gockel Drug Quality Assurance: Systems at ChemCon Author: Dr. Peter Gockel On February 13th, 2006, the FOOD AND DRUG ADMINISTRATION (FDA) implemented a revision to the Compliance Program Guidance Manual for active

More information

How to Get ISO Certified

How to Get ISO Certified People frequently ask me where to locate information about ISO 13485, so this whitepaper was written specifically to address their needs, as well as review in detail the six steps to preparing for ISO

More information

Global Development of Drugs and Co-operation among Asian Economies

Global Development of Drugs and Co-operation among Asian Economies Global Development of Drugs and Co-operation among Asian Economies Chi-Chou Liao, Ph.D. Director General Bureau of Pharmaceutical Affairs, Department of Health, Chinese Taipei 2006 Symposium on Asia Pacific

More information

David W Feigal, Jr., MD MPH

David W Feigal, Jr., MD MPH Global Harmonization Summit Where have we been with Harmonization? David W Feigal, Jr., MD MPH Adjunct Professor, College of Law, Arizona State University Partner, NDA Partners LLP September 18, 2014 Washington

More information

GxP Auditing, Remediation, and Staff Augmentation

GxP Auditing, Remediation, and Staff Augmentation GxP Auditing, Remediation, and Staff Augmentation TABLE OF CONTENTS 3 Introduction 4 GxP Auditing 4 GMP Auditing 5 GCP Auditing 6 GLP Auditing 7 Pharmacovigilance Auditing 7 Vendor/Supplier Auditing 8

More information

Safety and Performance Grading of Quality Management System Nonconformities

Safety and Performance Grading of Quality Management System Nonconformities Safety and Performance Grading of Quality Management System Nonconformities CAPT Kimberly Lewandowski-Walker FDA/ORA/Office of Medical Products and Tobacco Operations National Expert, Medical Devices Goal

More information

excipients Setting the Scene

excipients Setting the Scene NSF/IPEC/ANSI 363: Good Manufacturing Practices (GMP) for Pharmaceutical Excipients Multiple stakeholders; one objective. Presented by Janeen Skutnik-Wilkinson International Pharmaceutical Excipients Council

More information

ISO 13485:2016. What s in it - and what does it mean?

ISO 13485:2016. What s in it - and what does it mean? ISO 13485:2016 What s in it - and what does it mean? QAdvis key competence areas Turn key quality systems Sharepoint based Digital signatures Efficient and lean Validated and compliant QMS in-the cloud

More information

GxP Auditing, Remediation, and Quality System Resourcing

GxP Auditing, Remediation, and Quality System Resourcing GxP Auditing, Remediation, and Quality System Resourcing TABLE OF CONTENTS 3 Introduction 4 GxP Auditing 4 GMP Auditing 5 GCP Auditing 6 GLP Auditing 7 Pharmacovigilance Auditing 7 Vendor/Supplier Auditing

More information

Prevent Quality System Deficiencies by Conducting Effective Internal Audits. Whitepaper

Prevent Quality System Deficiencies by Conducting Effective Internal Audits. Whitepaper Prevent Quality System Deficiencies by Conducting Effective Internal Audits Whitepaper An internal audit system is one of the most effective ways to monitor, analyze, control, and improve quality management

More information

Introduction and Case Sharing of FDA CGMP Inspections

Introduction and Case Sharing of FDA CGMP Inspections Presentation title Date Introduction and Case Sharing of FDA CGMP Inspections Second Russian GMP Conference 2017 Andrew Chang, Ph.D Vice President, Quality and Regulatory Compliance Novo Nordisk A/S Presentation

More information

Optimising the management of post-approval changes for patients timely access to medicines

Optimising the management of post-approval changes for patients timely access to medicines Optimising the management of post-approval changes for patients timely access to medicines The industry perspectives with a Pledge for Convergence 7th APAC, April 2018 Sannie Chong (Ph.D. FRSC) Asia Pacific

More information

Medtech: Global Regulatory Strategy in Medical Device Product Development

Medtech: Global Regulatory Strategy in Medical Device Product Development Medtech: Global Regulatory Strategy in Medical Device Product Development We contribute to healthcare For Medical Device & Drug May Ng Director, Regulatory & Quality Consultant may.ng@arq-on.com Disclaimer:

More information

AS9101 Revision E Understanding the Changes

AS9101 Revision E Understanding the Changes AS9101 Revision E Understanding the Changes Introduction Aviation, space and defense (ASD) organizations are highly regulated to ensure their products are safe and reliable, conform to statutory and regulatory

More information

Process validation in medical devices

Process validation in medical devices Process validation in medical devices Fulfil requirements with expert regulatory guidance 1TÜV SÜD Contents INTRODUCTION 4 VALIDATION PLANNING 5 INSTALLATION QUALIFICATION 7 OPERATIONAL QUALIFICATION 9

More information

Process validation in medical devices

Process validation in medical devices Process validation in medical devices Fulfil requirements with expert regulatory guidance 1TÜV SÜD Contents INTRODUCTION 4 VALIDATION PLANNING 5 INSTALLATION QUALIFICATION 7 OPERATIONAL QUALIFICATION 9

More information

LIFE SCIENCE BENCHMARKING STUDY. Trends and Best Practices Based on Our Work with the US FDA and Over 250 Companies

LIFE SCIENCE BENCHMARKING STUDY. Trends and Best Practices Based on Our Work with the US FDA and Over 250 Companies LIFE SCIENCE 01 BENCHMARKING STUDY Trends and Best Practices Based on Our Work with the US FDA and Over 0 Companies SUMMARY In this report, UL EduNeering has identified the 01/01 compliance and business

More information

ISO13485: An Overview - Gunter Frey Member, SG3 NEMA

ISO13485: An Overview - Gunter Frey Member, SG3 NEMA ISO13485:2003 - An Overview - Member, SG3 NEMA Americas (FDA/CMDR) Regulatory Authorities Europe (Competent Authorities) A Global View India (AERB) Singapore (HSA) Thai FDA Malaysian Govt Russia (GHOST)

More information

Excipient GMP GDP Certification Project. Presentation to FECC Seminar Brussels 19 th March 2009 Dr Iain Moore Chair GMP Committee IPEC Europe

Excipient GMP GDP Certification Project. Presentation to FECC Seminar Brussels 19 th March 2009 Dr Iain Moore Chair GMP Committee IPEC Europe Excipient GMP GDP Certification Project Presentation to FECC Seminar Brussels 19 th March 2009 Dr Iain Moore Chair GMP Committee IPEC Europe Excipient GMP GDP and Certification 1. Basis for Project 2.

More information

QMS Aspects of the MDR (& IVDR)

QMS Aspects of the MDR (& IVDR) QMS Aspects of the MDR (& IVDR) Vicky Medley Global QMS Manager Medical Devices 27 February 2018 Copyright 2018 BSI. All rights reserved This Presentation 1. The clock is ticking! 2. Dates & priorities

More information

Implementation of 2005 Pharmaceutical Affairs Law and ICH Q8-Q10 in Japan

Implementation of 2005 Pharmaceutical Affairs Law and ICH Q8-Q10 in Japan JCCT workshop on Q8/Q9/Q10 Beijing Implementation of 2005 Pharmaceutical Affairs Law and ICH Q8-Q10 in Japan Yukio HIYAMA Chief, 3 rd Section, Division of Drugs National Institute of Health Sciences, Ministry

More information

Staffing - Medical Devices

Staffing - Medical Devices Staffing - Medical Devices LONDON GENEVA SINGAPORE DUBLIN procorre.com 1 Implementing solutions to clients worldwide 2 Contents Services 04 Sector Overview 07 Medical Devices 07 In-Vitro Diagnostics 08

More information

Regulatory Framework in Japan - Past and Future - Building a Regulatory Framework Essential Elements of Compliance / Surveillance

Regulatory Framework in Japan - Past and Future - Building a Regulatory Framework Essential Elements of Compliance / Surveillance Regulatory Framework in Japan - Past and Future - Building a Regulatory Framework Essential Elements of Compliance / Surveillance Nobuo UEMURA Director Office of Medical Devices III Pharmaceuticals and

More information

An overview of international initiatives in the regulatory sphere

An overview of international initiatives in the regulatory sphere The place of the Certification Procedure in the global regulatory environment 19/20 September 2017, Prague, Czech Republic An overview of international initiatives in the regulatory sphere Cordula Landgraf

More information

Effective Quality Oversight of Pharmaceutical Contract Manufacturing Organizations (CMOs)

Effective Quality Oversight of Pharmaceutical Contract Manufacturing Organizations (CMOs) Effective Quality Oversight of Pharmaceutical Contract Manufacturing Organizations (CMOs) *** LIMITED TIME OFFER: FREE $100 AMAZON GIFT CARD! *** REGISTER TODAY! The globalization of the pharmaceutical

More information

Update on the International Medical Device Regulators Forum

Update on the International Medical Device Regulators Forum Update on the International Medical Device Regulators Forum Melissa Torres, ME, MS Associate Director for International Affairs Office of the Center Director Center for Devices and Radiological Health

More information

Shift from Approved Vendor to Strong Supply Chain Partner

Shift from Approved Vendor to Strong Supply Chain Partner Shift from Approved Vendor to Strong Supply Chain Partner Presented by Randall D Amico November 10, 2015 11/11/2015 Slide 1 Our heritage: 149 years of business success 1866 1906 Establishment of a Mannheim-based

More information

1. PMDA Chief Executive Dr. Kondo s New Year message for 2015

1. PMDA Chief Executive Dr. Kondo s New Year message for 2015 PMDA Updates January, 2015 Camellia japonica News 1. PMDA Chief Executive Dr. Kondo s New Year message for 2015 A Happy New Year to all of you. PMDA has been promoting regulatory science through the operation

More information

to protect human health throughout the life-cycle of medicinal products;

to protect human health throughout the life-cycle of medicinal products; ICMRA Communications Strategy: 2018-2020 Introduction The International Coalition of Medicines Regulatory Authorities (ICMRA) is a voluntary, highlevel, strategic coordinating, advocacy and leadership

More information

ISO FDA QSR. ISO and FDA QSR: A Step by Step Guide to Complying with Medical Device QMS Requirements

ISO FDA QSR. ISO and FDA QSR: A Step by Step Guide to Complying with Medical Device QMS Requirements ISO 13485 FDA QSR ISO 13485 and FDA QSR: A Step by Step Guide to Complying with Medical Device QMS Requirements Jon Speer Founder & VP of QA/RA greenlight.guru Table of Contents 1 Introduction 4 QMS Philosophy

More information

Self-Inspection and its potential benefits via ICH Q9 & Q10

Self-Inspection and its potential benefits via ICH Q9 & Q10 Self-Inspection and its potential benefits via ICH Q9 & Q10 Kevin O Donnell, Ph.D. Senior Inspector & Market Compliance Manager Irish Medicines Board IMB Information Day October 23 rd, 2008 Slide 1 Topics

More information

U.S. FDA CENTER FOR DEVICES AND RADIOLOGICAL HEALTH UPDATE. Jeff Shuren Director Center for Devices and Radiological Health

U.S. FDA CENTER FOR DEVICES AND RADIOLOGICAL HEALTH UPDATE. Jeff Shuren Director Center for Devices and Radiological Health U.S. FDA CENTER FOR DEVICES AND RADIOLOGICAL HEALTH UPDATE Jeff Shuren Director Center for Devices and Radiological Health 21 ST CENTURY CURES ACT IMPLEMENTATION Provision Implementation activities completed

More information

Conduct a More Effective Management Review. Rob Packard, Consultant

Conduct a More Effective Management Review. Rob Packard, Consultant Conduct a More Effective Management Review & Slide 1 of 31 Your Speaker Rob Packard Rob Packard is a regulatory consultant with 20 years experience in the medical device, pharmaceutical and biotechnology

More information

EU MDR 10 Things Packaging Engineers Should Know

EU MDR 10 Things Packaging Engineers Should Know EU MDR 10 Things Packaging Engineers Should Know networkpartners.com NUMBER ONE THE TIME FOR ACTION IS NOW First, some background: The EU Medical Device Regulation (MDR) was approved by the European Parliament

More information

Medical Device Communiqué

Medical Device Communiqué Medical Device Communiqué Q2 2013 Demonstrating the Safety of Medical Devices in the Human Body 1 DOJ: The Focus is on GMPs in 2013 2 ROHS II Impacts Medical Device Companies 3 Demonstrating the Safety

More information

COMBINATION PRODUCTS Inspection Readiness and Outcomes

COMBINATION PRODUCTS Inspection Readiness and Outcomes WHITE PAPER COMBINATION PRODUCTS Inspection Readiness and Outcomes Many companies think that because they have a good relationship with the FDA Center they interacted with during their submission reviews

More information

QMS regulation in Japan. Office of Manufacturing/Quality and Compliance As of 1st April, 2015

QMS regulation in Japan. Office of Manufacturing/Quality and Compliance As of 1st April, 2015 QMS regulation in Japan Office of Manufacturing/Quality and Compliance As of 1st April, 2015 Manufacturing/Quality and Compliance Manufacturing/Quality and Compliance QA of GMP/QMS GMP QMS KANSAI Branch

More information

Quality Manual. Print Name Title Date Prepared by L Naughton QA Consultant 9 th April 09. Reviewed by Bernard Lennon Fire and Safety Officer

Quality Manual. Print Name Title Date Prepared by L Naughton QA Consultant 9 th April 09. Reviewed by Bernard Lennon Fire and Safety Officer Quality Manual Print Name Title Date Prepared by L Naughton QA Consultant 9 th April 09 Reviewed by Bernard Lennon Fire and Safety Officer 9 th April 09 Corporate Authorisation Joe Hoare Estates Officer

More information

Global Medical Device QA/RA Consulting

Global Medical Device QA/RA Consulting EmergoGroup.com Global Medical Device QA/RA Consulting More than 2,800 companies trust Emergo to achieve and maintain compliance with global medical device and IVD regulations. Core Areas of Expertise

More information